Detail akcie CryoPort online

Business Summary: Cryoport, Inc. provides temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. The Company supports biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products. Its integrated supply chain platform includes the Cryoportal Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems. The Company's segments include Life Sciences Services and Life Sciences Products. The Company's Life Sciences Services segment provides cryogenic biostorage within the life science industry through direct sales. Its Life Sciences Products segment manufactures and sells cryogenic freezers, cryogenic dewars and accessories within the life science industry through direct sales or a distribution network.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, CryoPort Inc revenues increased 13% to $130.7M. Net loss applicable to common stockholders excluding extraordinary items decreased 66% to $31.4M. Revenues reflect Life Sciences Services segment increase from $21.6M to $49M, Life Sciences Products segment increase from $18.1M to $37.5M, Resources and Managers segment increase of 15% to $44.2M, Americas segment increase of 17% to $98.6M.